Haematological actions of androgens

Best Pract Res Clin Endocrinol Metab. 2022 Sep;36(5):101653. doi: 10.1016/j.beem.2022.101653. Epub 2022 Apr 1.

Abstract

In this review, we discuss the effects on androgens on the haemopoietic system, focussing largely on the effects of testosterone on erythropoiesis. Stimulation of erythropoiesis is one of the most consistent effects of testosterone treatment observed in clinical trials. In men with anaemia this effect can be beneficial. Conversely, erythrocytosis is one of the most common adverse effects of testosterone treatment with a relative risk of 8.14 (95% CI: 1.87-35.40) estimated by a recent meta-analysis of randomised placebo controlled clinical trials. A reduction in haemoglobin is commonly seen in men receiving androgen deprivation therapy for prostate cancer, and in transwomen receiving gender affirming therapy to reduce serum testosterone. While mechanisms by which androgens regulate erythropoiesis are not fully understood, it is likely that effects on erythropoietic progenitor cells and erythropoietin are involved, with secondary effects on iron metabolism. In contrast, whether androgens exert clinically relevant effects on white blood cells and on platelets requires further study.

Keywords: erythropoietin; haematocrit; haematopoiesis; iron; testosterone.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists / therapeutic use
  • Androgens / adverse effects
  • Erythropoietin* / therapeutic use
  • Hemoglobins / metabolism
  • Hemoglobins / therapeutic use
  • Humans
  • Iron / therapeutic use
  • Male
  • Prostatic Neoplasms* / chemically induced
  • Prostatic Neoplasms* / drug therapy
  • Testosterone / adverse effects
  • Testosterone / therapeutic use

Substances

  • Androgen Antagonists
  • Androgens
  • Hemoglobins
  • Erythropoietin
  • Testosterone
  • Iron